240 related articles for article (PubMed ID: 25562656)
1. Modeling the natural history of Pelizaeus-Merzbacher disease.
Mayer JA; Griffiths IR; Goldman JE; Smith CM; Cooksey E; Radcliff AB; Duncan ID
Neurobiol Dis; 2015 Mar; 75():115-30. PubMed ID: 25562656
[TBL] [Abstract][Full Text] [Related]
2. Neural stem cells restore myelin in a demyelinating model of Pelizaeus-Merzbacher disease.
Gruenenfelder FI; McLaughlin M; Griffiths IR; Garbern J; Thomson G; Kuzman P; Barrie JA; McCulloch ML; Penderis J; Stassart R; Nave KA; Edgar JM
Brain; 2020 May; 143(5):1383-1399. PubMed ID: 32419025
[TBL] [Abstract][Full Text] [Related]
3. Novel pathologic findings in patients with Pelizaeus-Merzbacher disease.
Laukka JJ; Kamholz J; Bessert D; Skoff RP
Neurosci Lett; 2016 Aug; 627():222-32. PubMed ID: 27222925
[TBL] [Abstract][Full Text] [Related]
4. Involvement of ER stress in dysmyelination of Pelizaeus-Merzbacher Disease with PLP1 missense mutations shown by iPSC-derived oligodendrocytes.
Numasawa-Kuroiwa Y; Okada Y; Shibata S; Kishi N; Akamatsu W; Shoji M; Nakanishi A; Oyama M; Osaka H; Inoue K; Takahashi K; Yamanaka S; Kosaki K; Takahashi T; Okano H
Stem Cell Reports; 2014 May; 2(5):648-61. PubMed ID: 24936452
[TBL] [Abstract][Full Text] [Related]
5. Pelizaeus-Merzbacher Disease: Molecular and Cellular Pathologies and Associated Phenotypes.
Inoue K
Adv Exp Med Biol; 2019; 1190():201-216. PubMed ID: 31760646
[TBL] [Abstract][Full Text] [Related]
6. Modeling the Mutational and Phenotypic Landscapes of Pelizaeus-Merzbacher Disease with Human iPSC-Derived Oligodendrocytes.
Nevin ZS; Factor DC; Karl RT; Douvaras P; Laukka J; Windrem MS; Goldman SA; Fossati V; Hobson GM; Tesar PJ
Am J Hum Genet; 2017 Apr; 100(4):617-634. PubMed ID: 28366443
[TBL] [Abstract][Full Text] [Related]
7. Chemical Screening Identifies Enhancers of Mutant Oligodendrocyte Survival and Unmasks a Distinct Pathological Phase in Pelizaeus-Merzbacher Disease.
Elitt MS; Shick HE; Madhavan M; Allan KC; Clayton BLL; Weng C; Miller TE; Factor DC; Barbar L; Nawash BS; Nevin ZS; Lager AM; Li Y; Jin F; Adams DJ; Tesar PJ
Stem Cell Reports; 2018 Sep; 11(3):711-726. PubMed ID: 30146490
[TBL] [Abstract][Full Text] [Related]
8. Pelizaeus-Merzbacher disease: Genetic and cellular pathogenesis.
Garbern JY
Cell Mol Life Sci; 2007 Jan; 64(1):50-65. PubMed ID: 17115121
[TBL] [Abstract][Full Text] [Related]
9. Axon-glial interaction in the CNS: what we have learned from mouse models of Pelizaeus-Merzbacher disease.
Gruenenfelder FI; Thomson G; Penderis J; Edgar JM
J Anat; 2011 Jul; 219(1):33-43. PubMed ID: 21401588
[TBL] [Abstract][Full Text] [Related]
10. A common mechanism of PLP/DM20 misfolding causes cysteine-mediated endoplasmic reticulum retention in oligodendrocytes and Pelizaeus-Merzbacher disease.
Dhaunchak AS; Nave KA
Proc Natl Acad Sci U S A; 2007 Nov; 104(45):17813-8. PubMed ID: 17962415
[TBL] [Abstract][Full Text] [Related]
11. Deletion of a splicing enhancer disrupts PLP1/DM20 ratio and myelin stability.
Wang E; Dimova N; Sperle K; Huang Z; Lock L; McCulloch MC; Edgar JM; Hobson GM; Cambi F
Exp Neurol; 2008 Dec; 214(2):322-30. PubMed ID: 18835559
[TBL] [Abstract][Full Text] [Related]
12. Oligodendrocyte Death in Pelizaeus-Merzbacher Disease Is Rescued by Iron Chelation.
Nobuta H; Yang N; Ng YH; Marro SG; Sabeur K; Chavali M; Stockley JH; Killilea DW; Walter PB; Zhao C; Huie P; Goldman SA; Kriegstein AR; Franklin RJM; Rowitch DH; Wernig M
Cell Stem Cell; 2019 Oct; 25(4):531-541.e6. PubMed ID: 31585094
[TBL] [Abstract][Full Text] [Related]
13. Neuronal loss in Pelizaeus-Merzbacher disease differs in various mutations of the proteolipid protein 1.
Sima AA; Pierson CR; Woltjer RL; Hobson GM; Golden JA; Kupsky WJ; Schauer GM; Bird TD; Skoff RP; Garbern JY
Acta Neuropathol; 2009 Oct; 118(4):531-9. PubMed ID: 19562355
[TBL] [Abstract][Full Text] [Related]
14. Gait abnormalities and progressive myelin degeneration in a new murine model of Pelizaeus-Merzbacher disease with tandem genomic duplication.
Clark K; Sakowski L; Sperle K; Banser L; Landel CP; Bessert DA; Skoff RP; Hobson GM
J Neurosci; 2013 Jul; 33(29):11788-99. PubMed ID: 23864668
[TBL] [Abstract][Full Text] [Related]
15. Suppression of proteolipid protein rescues Pelizaeus-Merzbacher disease.
Elitt MS; Barbar L; Shick HE; Powers BE; Maeno-Hikichi Y; Madhavan M; Allan KC; Nawash BS; Gevorgyan AS; Hung S; Nevin ZS; Olsen HE; Hitomi M; Schlatzer DM; Zhao HT; Swayze A; LePage DF; Jiang W; Conlon RA; Rigo F; Tesar PJ
Nature; 2020 Sep; 585(7825):397-403. PubMed ID: 32610343
[TBL] [Abstract][Full Text] [Related]
16. Pelizaeus-Merzbacher disease: on the cusp of myelin medicine.
Elitt MS; Tesar PJ
Trends Mol Med; 2024 May; 30(5):459-470. PubMed ID: 38582621
[TBL] [Abstract][Full Text] [Related]
17. A novel PLP1 frameshift mutation causing a milder form of Pelizaeus-Merzbacher disease.
Shiihara T; Watanabe M; Moriyama K; Uematsu M; Sameshima K
Brain Dev; 2015 Apr; 37(4):455-8. PubMed ID: 25043250
[TBL] [Abstract][Full Text] [Related]
18. PLP overexpression perturbs myelin protein composition and myelination in a mouse model of Pelizaeus-Merzbacher disease.
Karim SA; Barrie JA; McCulloch MC; Montague P; Edgar JM; Kirkham D; Anderson TJ; Nave KA; Griffiths IR; McLaughlin M
Glia; 2007 Mar; 55(4):341-51. PubMed ID: 17133418
[TBL] [Abstract][Full Text] [Related]
19. Clinically relevant intronic splicing enhancer mutation in myelin proteolipid protein leads to progressive microglia and astrocyte activation in white and gray matter regions of the brain.
Bachstetter AD; Webster SJ; Van Eldik LJ; Cambi F
J Neuroinflammation; 2013 Dec; 10():146. PubMed ID: 24314267
[TBL] [Abstract][Full Text] [Related]
20. The molecular and cellular defects underlying Pelizaeus-Merzbacher disease.
Woodward KJ
Expert Rev Mol Med; 2008 May; 10():e14. PubMed ID: 18485258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]